Recent Updates in Novel Therapeutics for the Treatment of Multiple Sclerosis
This CME activity will focus on the treatment of multiple sclerosis with recent updates in novel therapeutics. Both new data and long‐term data of available therapies show that patients are able to achieve disease activity free status while receiving these therapies. Expert faculty will discuss the treatment of acute relapses in multiple sclerosis. At the conclusion of this program, clinicians will be better equipped to treat relapses in patients with multiple sclerosis.
This activity has been designed to meet the educational needs of neurologists and healthcare professionals responsible for the diagnosis, treatment or management of patients with multiple sclerosis.
Upon completion of this activity, participants will be able to:
- Discuss the pathophysiology and characteristics of disease progression within multiple sclerosis.
- Evaluate available efficacy and safety data of novel targeted antibodies for the treatment of multiple sclerosis.
Fred D. Lublin, MD
Clyde E. Markowitz, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
Fred D. Lublin, MD
Consultant/Advisor: AbbVie Inc.; Acorda Therapeutics Inc.; Actelion Pharmaceuticals US, Inc.; Akros Pharma Inc.; Amgen Inc.; Atara Biotherapeutics; Bayer AG; Biogen; EMD Serono, Inc.; Genentech, Inc.; Genzyme Corporation; Forward Pharma A/S; Mallinckrodt; MedDay; MedImmune; Novartis AG; Osmotica Pharmaceutical Corp.; Teva Pharmaceutical Industries Ltd.; TG Therapeutics, Inc.; Toyama Pharmaceutical Co. Ltd; XenoPort, Inc.
Grant/Research Support: Biogen; Genzyme Corporation; Celgene Corporation; National Institutes of Health; National Multiple Sclerosis Society; Novartis AG; Teva Pharmaceutical Industries Ltd.; Transparency Life Sciences
Speaker's Bureau: Genentech, Inc.; Genzyme Corporation
Stock Ownership: Cognition Pharmaceuticals, Inc.
Clyde E. Markowitz, MD
Consultant/Advisor: Bayer AG; Biogen; EMD Serono, Inc.; Genentech, Inc.; Genzyme Corporation; Novartis AG; Opexa Therapeutics, Inc.; F. Hoffmann-La Roche Ltd; Teva Pharmaceutical Industries Ltd.
Non-faculty: Sandy Breslow; Alison Kemp; Leah Johnson; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Nicole Brestowski; Chelsey Benedek and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the last 12 months.
This CME activity has been supported by an independent educational grant from Mallinckrodt Pharmaceuticals.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Acceditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Mallinckrodt Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.25 AMA PRA Category 1 Credit(s)™
- 0.25 Non-physician